Skip to main content
CRSP logo

CRISPR Therapeutics AG (CRSP) Stock: Price, Forecast & Analyst Target

CRISPR Therapeutics AG (CRSP) — MoonshotScore 22/100 (Weak band), calculated Nov 18, 2026. Price $39.10 (+0.44%), as of the Nov 20, 2026 trading session; market cap $3.79B.

Educational signal · not a buy or sell recommendation · How to read this

$39.10 +$0.17 (+0.44%) Market Cap $3.79B

CRISPR Therapeutics AG · CRSP · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: CRSP is a gene-editing biotechnology company with a portfolio of investigational therapies for blood disorders, cancers, and rare conditions using CRISPR and Cas technology. The decisive question is whether the flagship ex vivo therapy advances to approval and market adoption before cash reserves diminish.

Price as of Nov 20, 2026

Key Statistics

22 of 100

MoonshotScore v2 · CRISPR Therapeutics AG (CRSP)

Weak
Business Quality Poor (13)
Financial Safety Okay (42)
Valuation Full (44)
Growth Durability Fading (34)
Momentum Quiet (50)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, weak growth and a full valuation, though the balance sheet is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Full; Growth Durability: Fading; Momentum: Quiet.

  • quarterly revenue $1M (Q1 FY2026, quarter ended Mar 2026)
  • EPS beat 0 of the last 4 reports
  • Altman Z 1.77 · Piotroski F 2

Holding back: weak fundamentals, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CRSP (53 recorded, newest six shown)
RecordedScoreBand
22Weak
22Weak
22Weak
22Weak
22Weak
22Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$39.10
Change on the day+0.44%
52-week range$39.10–$63.45
Market capitalisation$3.79B—
Shares traded on the day3.32M
Beta (volatility vs the S&P 500)1.9

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $39, high $69, latest $39. $69 $39 high $69 Oct 17, 2025 Nov 20, 2026 · $39 $69Oct 17, 2025$64Oct 31, 2025$53Nov 14, 2025$53Nov 28, 2025$57Dec 12, 2025$55Dec 26, 2025$54Jan 9, 2026$56Jan 23, 2026$49Feb 6, 2026$53Feb 20, 2026$57Mar 6, 2026$46Mar 20, 2026$50Apr 2, 2026$58Apr 17, 2026$52May 1, 2026$48May 15, 2026$56May 29, 2026$50Jun 12, 2026$55Jun 26, 2026$53Jul 10, 2026$47Jul 24, 2026$54Aug 7, 2026$60Aug 21, 2026$56Sep 4, 2026$57Sep 18, 2026$55Oct 2, 2026$49Oct 16, 2026$51Oct 30, 2026$42Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for CRISPR Therapeutics AG (CRSP): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Neutral
Valuation Neutral
Growth Durability Weak
Momentum Neutral

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Debt/Equity Neutral
ROE Negative
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is CRISPR Therapeutics AG (CRSP), and what does it report?

Short answer · as of

CRSP develops ex vivo and in vivo gene-edited therapies targeting hemoglobinopathies, malignancies, and rare diseases.

The flagship ex vivo therapy modifies patients' own hematopoietic stem cells to boost fetal hemoglobin production in red blood cells for sickle cell disease and beta-thalassemia. The company pursues allogeneic CAR-T candidates and a stem cell-derived immune-evasive product for type diabetes. The income statement reflects a pre-revenue biotech model: revenues minimal, operating expenses substantial, with burn driven by clinical programs and development infrastructure.

Partnerships with Bayer, Vertex, and others provide capital infusions and potentially offset some burn, but do not materially reduce cash consumption needs. The path to profitability requires the lead program or another candidate to reach market and generate significant royalties or milestone payments.

2 · Latest results

What do the latest results show for CRISPR Therapeutics AG (CRSP)?

Short answer · as of

The most recent reported quarter, Q1 FY2026, carried revenue of $1M.

Recent quarters show losses have tightened from prior periods, with the most recent quarter missing earnings expectations narrowly while revenue came in ahead of forecast, an unusual outcome for pre-revenue biotech. This improvement reflects operational discipline in spending and, crucially, the beginning of royalty revenue from partnership arrangements. The gross margin on limited revenue is highly positive, a signal that when scale arrives, unit economics will be favorable.

The near-term catalyst is regulatory progress on the lead program. Evidence of approval momentum or expanded partnership payments would improve burn and extend runway. Conversely, a clinical setback or partner de-emphasis would pressure the timeline and valuation.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2026$1M-$123M-$1.28 (diluted)
Q2 FY2026$10M-$91M-$0.94 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for CRISPR Therapeutics AG (CRSP)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

The company holds substantial cash and short-term investments relative to its annual burn, providing visibility into a runway that extends several years into the future even without additional capital infusions. This cash position is a major strength in a sector where many biotech firms burn through liquidity quickly. The current ratio and quick ratio are exceptionally strong, indicating no near-term solvency pressure.

However, the path to cash flow positivity depends on program success. Debt is modest and well-covered. The distress screens show warning signs in the negative net margin and return metrics, which are expected for a pre-commercial biotech but would be concerning if cash runway tightens.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.77 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-25.6%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at CRISPR Therapeutics AG (CRSP)?

Short answer · as of

Current published price targets run low $52.00 · high $110.00 · consensus $72.43 · median $70.00 against a quoted price of $39.10 (as of Nov 20, 2026).

Watch for regulatory milestone announcements on the lead program, particularly topline efficacy and safety data. The company guided that capital runway extends through multiple coming years, so focus will be on development milestones, not financing urgency. Analyst estimates for profitability remain pessimistic through the decade, reflecting the probability that revenue does not materialize if trials encounter unexpected risks.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q1 FY2026) was filed May 4, 2026 — 6 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does CRISPR Therapeutics AG compare with its peers?

Short answer

CRISPR Therapeutics AG's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Definium operates in a competitive space with multiple companies advancing mood and neurodevelopmental treatments. Differentiation rests on the specific mechanism and the trial design. The company's focus on leading programs sits against a competitive landscape including larger pharmaceutical incumbents with diversified pipelines. Scale and capitalization are asymmetric.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ADMA Biologics, Inc. (ADMA) Same industry, near in market value$13.17 Nov 20, 2026$2.92B97 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Named competitor$308.89 Nov 20, 2026$9.15B96 5-pillar Nov 18, 2026
Vericel Corporation (VCEL) Same industry, near in market value$57.52 Nov 20, 2026$2.94B95 5-pillar Nov 18, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Same industry, near in market value$26.36 Nov 20, 2026$3.33B89 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$39.91 Nov 20, 2026$4.37B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$17.58 Nov 20, 2026$5.04B83 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$46.53 Nov 20, 2026$3.42B72 5-pillar Nov 18, 2026
ACADIA Pharmaceuticals Inc. (ACAD) Same industry, near in market value$17.59 Nov 19, 2026$3.04B68 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$13.61 Nov 20, 2026$4.78B67 5-pillar Nov 18, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Same industry, near in market value$26.02 Nov 20, 2026$3.35B66 5-pillar Nov 18, 2026
Tango Therapeutics, Inc. (TNGX) Same industry, near in market value$21.73 Nov 20, 2026$3.68B62 5-pillar Nov 18, 2026
Vaxcyte, Inc. (PCVX) Named competitor$55.39 Nov 20, 2026$8.77B51 5-pillar Nov 18, 2026
CRISPR Therapeutics AG (CRSP) — this page$39.10$3.79B22

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$52.00 – $110.00
Consensus target
$72.43
Median target
$70.00

Consensus record · Captured .

Measured against a quoted price of $39.10 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 4, 2026

Transactions
36
Identified insiders
9
Purchases
0
Sales
7
Other transactions
29

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CRSP in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20263.20%$556.34MAdded +6.3% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about CRISPR Therapeutics AG (CRSP)?

Read these with our analysis →

Common Questions About CRSP (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

What is the lead ex vivo therapy?

This ex vivo gene-edited therapy modifies patients' own blood-forming stem cells to produce high levels of fetal hemoglobin, which prevents the sickling or crystallization that causes pain and organ damage in sickle cell disease and beta-thalassemia. It is the company's most advanced program and the basis of partnerships with Bayer and Vertex that provide royalty and milestone revenue. Approval and commercial launch would be transformative for CRSP's valuation and cash position. The addressable patient population is sizable but defined, so realistic expectations matter.

How long can the company operate at current burn rates?

The company has substantial cash and minimal debt, providing a runway that extends several years even without additional partnering or capital raises. The quarterly operating cash burn is in the range of hundreds of millions annualized, well below the cash on hand. However, this runway is not infinite. Acceleration of programs or increased headcount could shorten it. Conversely, additional partnership milestones or strategic capital raises could extend it indefinitely.

What are the key clinical risks?

The lead program must demonstrate durability of effect, safety over long follow-up periods, and consistent manufacturing to advance through late-stage trials. Off-target gene editing, immune responses, and manufacturing variability are known risks in the CRISPR space. Clinical trials could fail or show safety signals that limit the addressable population. The in vivo programs for liver, lung, muscle, and central nervous system disorders face additional hurdles around tissue delivery and specificity that are not yet fully solved.

Does insider activity suggest confidence in near-term progress?

Insider transactions over the recent window show sales but also grants and awards, a mix typical of pre-revenue biotech. The sales clustered around certain dates and price ranges, suggesting opportunistic trimming rather than wholesale confidence abandonment. The net of insider activity is small relative to the institution's positions, so it is not a strong signal in either direction.

What is the CRSP stock price today?

The last price recorded for CRISPR Therapeutics AG (CRSP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CRSP price target?

The analyst consensus price target for CRISPR Therapeutics AG (CRSP), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours)
  • 1. What is CRISPR Therapeutics AG (CRSP), and what does it report?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for CRISPR Therapeutics AG (CRSP)?: Reported versus estimated, last 8 quarters; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • 3. What are the financial strengths and risks for CRISPR Therapeutics AG (CRSP)?: Cash, investments and debt; Cash and short-term investments over time (USD millions); Trailing twelve-month ratio set
  • 4. What should you watch next at CRISPR Therapeutics AG (CRSP)?: Analyst revenue and earnings estimates (average); Cash runway cross-check (ours)
  • 5. How does CRISPR Therapeutics AG compare with its peers?: Business description; Employees; Annual revenue and net result (USD millions)
  • FAQ: What is the lead ex vivo therapy?: Business description; Analyst actions, most recent per firm
  • FAQ: How long can the company operate at current burn rates?: Cash, investments and debt; Operating cash flow by quarter (USD millions); Cash runway cross-check (ours)
  • FAQ: What are the key clinical risks?: Business description; Analyst revenue and earnings estimates (average); Cash, investments and debt
  • FAQ: Does insider activity suggest confidence in near-term progress?: Insider transactions, last 180 days; Institutional ownership (13F); Largest 5 institutional holders
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold CRSP

Funds in our ETF coverage that list CRSP among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
ARK Innovation ETF (ARKK)4.73%